Education
About Us
Working with TipRanks
Follow Us
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
TVRD Stock Chart & Stats
$3.90
--
Market closed
$3.90
--
Day’s Range― - ―
52-Week Range$3.74 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$38.09M
Enterprise Value$16.05M
Total Cash (Recent Filing)$40.99M
Total Debt (Recent Filing)$254.00K
Price to Earnings (P/E)―
Beta0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.62
Price to Sales (P/S)1.04
P/FCF Ratio-0.12
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit2.50
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$9.00Price Target Upside130.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Signals In IPFPost-hoc analyses reported consistent reductions in lung fibrosis markers along with supportive imaging and lung-function trends, suggesting STAT3 inhibition may slow disease progression in idiopathic pulmonary fibrosis.
Next-generation Drug Tolerability And BioavailabilityA next-generation STAT3 inhibitor was engineered to improve gastrointestinal tolerability and show high oral bioavailability in animal studies, indicating future formulations could reduce diarrhea and broaden dosing options.
Upcoming Clinical Readouts As CatalystsAnticipated readouts from liver cancer studies and the first-in-human evaluation of the next-generation inhibitor are positioned as potential catalysts that could materially change the company outlook if they confirm efficacy and improved tolerability.
Bears Say
Combination Therapy Tolerability RisksAdverse-event-driven discontinuations were notably higher when the drug was combined with another antifibrotic, highlighting safety concerns for combination regimens and potential limits to clinical use.
Trial Discontinuations Clouding Efficacy AssessmentHigh rates of early treatment discontinuation in earlier trials complicate interpretation of efficacy signals and increase uncertainty around the true clinical benefit.
Valuation Concerns And Analyst ObjectivityDisclosure of potential conflicts of interest by the covering firm and a material downward adjustment to the model after removing anticipated IPF revenue raise questions about valuation reliability and analyst objectivity.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $3.74 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $38.09M.
When is Tvardi Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tvardi Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (130.77% Upside)
$9.00 (130.77% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.48%
12-Months-Change
Fundamentals
Return on Equity
-97.61%
Trailing 12-Months
Asset Growth
-39.65%
Trailing 12-Months
Company Description
Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Stock 12 Month Forecast
Average Price Target
$9.00
▲(130.77% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
13.09% Insiders
7.61% Mutual Funds
11.16% Other Institutional Investors
61.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---